#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancerПодробнее

Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancerПодробнее

#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02Подробнее

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim dataПодробнее

#ESMO22 Highlights on pembrolizumab with CRT in locally advanced HNSCC: The KEYNOTE-412 studyПодробнее

Metastatic breast cancer at ESMO 2022: TROPiCS02, MONARCH 3 and SYNERGYПодробнее

Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancerПодробнее

MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancerПодробнее

Highlights from ESMO Breast Cancer 2022Подробнее

#ESMO22 Highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. RCC: COSMIC-313Подробнее

Breast cancer trials of interest at ESMO 2022Подробнее

postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapyПодробнее

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BCПодробнее

ESMO 2022: Breast cancer highlightsПодробнее

Expert commentary: MONARCH 3 trial | Rodrigo DienstmannПодробнее

#ESMO22 Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 studyПодробнее

Abemaciclib for HR+/HER2- advanced or metastatic breast cancerПодробнее